Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 4, Issue 3, Pages 329-332Publisher
AMER CHEMICAL SOC
DOI: 10.1021/ml3003567
Keywords
Alzheimer's disease; beta-amyloid; ruthenium(III) complex
Categories
Funding
- Beneficentia Stiftung
Ask authors/readers for more resources
Metal complexes represent today an attractive class of experimental and-Alzheimer agents with the potential of blocking beta-amyloid 1-42 aggregation and scavenging its toxicity. Three representative ruthenium(III) complexes, namely NAMI A, KP1019, and PMRU20, were specifically evaluated to this end in an established in vitro model of AD relying on primary cortical neurons. Notably, PMRU20 turned out to be highly effective in protecting cortical neurons against A beta 1-42 toxicity, while the other tested ruthenium compounds were poorly active or even inactive; we also found that PMRU20 is virtually devoid of any significant toxicity in vitro at the applied concentrations. Interestingly, PMRU20 was neuroprotective even against the toxicity induced by A beta 25-35. The direct reaction of PMRU20 with A beta 1-42 was explored through ESI MS analysis and some adduct formation evidenced. In addition, thioflavin T assays revealed that PMRU20 greatly reduces A beta 1-42 aggregation. The implications of these findings are discussed in relation to emerging treatment strategies for the Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available